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Abstract
Combining potential diagnostics markers might be necessary to achieve sufﬁcient diagnostic test performance
in a complex state such as cancer. Applying this philosophy, we have identiﬁed a 13-protein, blood-based
classiﬁer for the detection of colorectal cancer. Using mass spectrometry, we evaluated 187 proteins in a
case-control study design with 274 samples and achieved a validation of 0.91 receiver operating characteristic
area under the curve.
Introduction: Colorectal cancer (CRC) testing programs reduce mortality; however, approximately 40% of the rec-
ommended population who should undergo CRC testing does not. Early colon cancer detection in patient populations
ineligible for testing, such as the elderly or those with signiﬁcant comorbidities, could have clinical beneﬁt. Despite
many attempts to identify individual protein markers of this disease, little progress has been made. Targeted mass
spectrometry, using multiple reaction monitoring (MRM) technology, enables the simultaneous assessment of groups
of candidates for improved detection performance.Materials and Methods: A multiplex assay was developed for 187
candidate marker proteins, using 337 peptides monitored through 674 simultaneously measured MRM transitions in a
30-minute liquid chromatography-mass spectrometry analysis of immunodepleted blood plasma. To evaluate the
combined candidate marker performance, the present study used 274 individual patient blood plasma samples, 137
with biopsy-conﬁrmed colorectal cancer and 137 age- and gender-matched controls. Using 2 well-matched platforms
running 5 days each week, all 274 samples were analyzed in 52 days. Results: Using one half of the data as a dis-
covery set (69 disease cases and 69 control cases), the elastic net feature selection and random forest classiﬁer
assembly were used in cross-validation to identify a 15-transition classiﬁer. The mean training receiver operating
characteristic area under the curve was 0.82. After ﬁnal classiﬁer assembly using the entire discovery set, the 136-
sample (68 disease cases and 68 control cases) validation set was evaluated. The validation area under the curve
was 0.91. At the point of maximum accuracy (84%), the sensitivity was 87% and the speciﬁcity was 81%. Conclusion:
These results have demonstrated the ability of simultaneous assessment of candidate marker proteins using high-
multiplex, targeted-mass spectrometry to identify a subset group of CRC markers with signiﬁcant and meaningful
performance.
Clinical Colorectal Cancer, Vol. 15, No. 2, 186-94ª 2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Classiﬁcation, Colorectal cancer, Machine learning, Mass spectrometry, Multiple reaction monitoringJ.J.J., B.E.W., and R.W.B. contributed equally to the present study.
1Applied Proteomics, Inc., San Diego, CA
2Applied Minds, Glendale, CA
3USC Norris Westside Cancer Center and USC Center for Applied Molecular Med-
icine, Beverly Hills, CA
Submitted: Jul 13, 2015; Accepted: Feb 3, 2016; Epub: Mar 25, 2016
Address for correspondence: John E. Blume, PhD, Applied Proteomics Inc., 3545 John
Hopkins Court, Suite 150, San Diego, CA 92121
E-mail contact: john@appliedproteomics.com
Clinical Colorectal Cancer June 2016
1533-0028/ª 2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.clcc.2016.02.004
Introduction
Colorectal cancer (CRC) remains a major cause of morbidity and
mortality in the United States, with 142,820 new cases and 50,830
deaths reported in 2013.1 In 2014, the American Cancer Society
reported that despite the establishment of CRC testing and pre-
vention guidelines2-4 and the demonstration of the efﬁcacy of such
programs,5 only 59.1% of those recommended to participate in
testing do so either by endoscopy (56.4%) or guaiac fecal occult
blood test (gFOBT; 8.8%).6
Recent methods have been proposed to improve the CRC
detection rates, including stool- and blood-based methods.7,8
Stool-based methods such as gFOBT and fecal immunochem-
ical test (FIT) have focused on the detection of blood released to
the lumen from cancerous lesions. Improvements in these
methods have combined additional markers (eg, methylated
DNA) to improve the performance.9 These methods have dis-
played varying performance, with 70% sensitivity and 93%
speciﬁcity and 70% sensitivity and 95% speciﬁcity for gFOBT
and FIT,10 respectively, and 92% sensitivity and 87% speciﬁcity
for ColoGuard.9 Although FIT has been suggested as an effec-
tive detection assay,11 a wide variation in test performance has
been observed, most likely resulting from varying test cutpoints
and sample handling conditions.12 Blood-based tests have long
been sought that will combine the assay performance of colo-
noscopy with the ease of plasma or serum collection and
handling. When patients refusing colonoscopy are offered alter-
native, noninvasive assay methods, the vast majority select
blood-based tests.13 Although some assay performance has been
demonstrated with certain blood-based markers such as
SEPT9,14 the clinical performance has not yet been sufﬁcient to
displace colonoscopy or FIT or gFOBT as a part of standard
clinical practice.
Many studies have attempted to identify new CRC markers with
clinical utility in either the blood plasma or serum15-18; however,
none has identiﬁed a single marker with sufﬁcient performance to
develop a clinically useful test. A few studies have attempted to
combine multiple markers for improved performance.19-21 How-
ever, these studies have suffered from technical limitations regarding
the number of analytes that can be combined in standard methods
such as immunoassays. Targeted mass spectrometry (MS) leverages
the multiplex properties of MS to simultaneously measure tens or
hundreds of target proteins.22-25 This approach has achieved
renewed recognition as a valuable analytical tool for protein mea-
surement.26,27 In the present study, we have implemented a
workﬂow that includes abundant protein immunodepletion and
targeted MS and real-time monitoring as a method to rapidly
evaluate 187 candidate CRC marker proteins, enabling the evalu-
ation of biomarker groups with signiﬁcantly better performance
than when used as single components. Using a collection of 274
CRC and control, age- and gender-matched patient plasma samples,
divided into discovery and validation sets, we validated a 13-protein
and 15-multiple reaction monitoring (MRM) transition classiﬁer
with signiﬁcant performance (area under the curve [AUC] 0.91;
87% sensitivity and 81% speciﬁcity). The present study demon-
strates the potential for high-multiplex, targeted MS to play a useful
role in biomarker panel discovery.Materials and Methods
Candidate Marker Proteins
A search of the published data was performed to compile a list of
candidate marker proteins with some degree of individual evidence
for CRC detection. The proteins considered for inclusion on the list
generally needed to be detectable in human blood serum or plasma
and to have been validated with some degree of CRC assay perfor-
mance in a reasonably sized human clinical study. An upper limit of
approximately 200 proteins was set, given the initial estimates on the
instrument limitations for concurrent data collection in a 30-minute
scheduled MRM assay. The selected proteins are listed in
Supplemental Table 1 (available in online). The assembled list was
not intended to be exhaustive or rigorously systematic but, rather, to
be a reasonable starting point for a discovery project evaluating the
potential for high multiplex-targeted MS to combine individual
analyte measurements into a higher performing group.
Targeted MS Assays
The peptide selection process for targeted MS using the MRM
system described in the present study (Figure 1) follows the guidelines
established in published MS standards24,28 and the selection criteria
outlined in the Clinical and Laboratory Standards Institute and Na-
tional Committee for Clinical Laboratory Standards guidelines.29-31
The initial 187 distinct proteins selected are represented by a total
of 310 known isoform variants as annotated in the Ensembl database.
In silico tryptic digestion was performed on this list of proteins,
resulting in 77,772 total peptides. Common peptide selection stra-
tegies were used to reduce the number to 9447 candidate peptides,
represented by 5904 unique sequences.32 The interim list of unique
peptides was further evaluated by in silico models that predict the
responsiveness in liquid chromatography (LC)-MS applications33; 5
to 6 peptides per protein, total of 1056, were selected for synthesis by
NewEngland Peptide (Gardner,MA) and empirical evaluation ofMS
performance. This analysis eliminated 430 peptides because of poor
ionization or excessive charge state distributions. A total of 3130
transitions from the remaining 626 peptides were evaluated using
triplicate 12-point dilution curves (1/2 log10 steps) in neat and
digested plasma matrices. Each transition’s dilution proﬁle was
assessed for linearity and accuracy of the ﬁt line to the dilution
response data and the precision of measurement at each dilution step.
Standard methods for the calculation of these metrics were used, for
which an acceptable peptide had to have  2 transitions that passed
the criteria for each metric.28 The acceptance criteria were as follows:
linearity (adjusted R2 values of > 0.95); accuracy (relative residual
values of < 0.80); and precision, coefﬁcient of variation values of <
0.25. This resulted in a multiplexed, targeted MS-MRM assay with a
total of 337 peptides with 2 transitions each that were then synthe-
sized as high purity (> 95%) stable isotope peptides (all C13) arginine
(R) or lysine (K; New England Peptide). Together with the C13-
labeled reference peptides, this yielded a ﬁnal assay with 1348
distinct analytes in a single 30-minute LC-MS injection. This qual-
iﬁes as a tier 2 MRM research assay design.34
CRC Samples
For the present initial discovery study, the CRC and control
plasma samples were obtained from 3 different commercial sampleClinical Colorectal Cancer June 2016 - 187
Figure 1 Flow Diagram Depicting the Steps Involved to Reduce an Initial List of Candidate Protein Biomarkers to a Viable Multiple
Reaction Monitoring Assay. In Brief, Target Proteins Underwent In Silico Tryptic Digestion From Which Peptides Were Down
selected by Both In Silico Modeling and Empirical Measurements to an Interim List of Candidate Peptides. These Candidate
Peptides Each Have 5 Transitions Optimized for Instrument Response and Evaluated for Matrix Interference. Additional Down
selection for the Final Assay, Based on Performance Metrics, Resulted in 337 Peptides, Having 2 Representative Transitions
per Each Peptide
Abbreviations: CRC ¼ colorectal cancer; LCMS ¼ liquid chromatography-mass spectrometry.
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188 -repositories for a total study collection of 274 age- and gender-
matched patients. A summary of the sample cohort characteristics
is listed in Table 1. The 3 repositories, CapitalBio (Gaithersburg,
MD), Asterand Bioscience (Detroit, MI), and ProteoGenex (Culver
City, CA), had previously collected samples from Russian pop-
ulations using their own institutionally approved protocols and
procedures. All patients with CRC had initially presented with
colon cancer, diagnosed by colonoscopy and subsequent pathologic
examination. The CapitalBio samples were collected from 3 sites
immediately before colonoscopy in advance of any procedure
medications. Blood samples were collected in 10-mL K2EDTA
tubes, processed to plasma by 1300g centrifugation within 30 mi-
nutes of sampling, and stored in polypropylene tubes at 70C
within 4 hours of collection. The Asterand Bioscience samples wereClinical Colorectal Cancer June 2016collected from 2 sites between the colonoscopy and resection sur-
gery. These blood samples were collected in K3EDTA tubes, pro-
cessed by double-centrifugation at 1500g, and frozen in 2-mL
cryovials at 70C within 4 hours of collection. The controls
samples for this group were collected after colonoscopy using the
same processing protocol after procedure conﬁrmation of the
absence of pathologic ﬁndings. The ProteoGenex samples were
collected from 2 sites on the day of resection before any preoperative
medications. The blood samples were collected in K2EDTA tubes,
processed to plasma by 1300g centrifugation, and stored in 2-mL
cryovials. The control samples for this group were collected using
the same processing protocol from healthy visits to a practitioner at
the same site, with the proviso that a gastrointestinal condition was
not the reason for the visit. The varied nature of the sample
Table 1 Summary of Patient Demographics and Clinical
Annotations for 138 Discovery Set and 136 Validation
Set Samples
Variable
Discovery
(n [ 138)
Validation
(n [ 136)
Control CRC Control CRC
Total 69 69 68 68
ProteoGenex 24 24 24 24
Asterand 24 24 24 24
CapitalBio 21 21 20 20
Gender
Male 29 29 28 28
Female 40 40 40 40
Mean age (years) 56.8 60.5 58.0 62.0
CRC stage NA NA
I 13 16
II 35 35
III 15 14
IV 6 3
CRC lesion location NA NA
Colon 33 39
Rectum 34 26
Rectosigmoid junction 2 3
Abbreviations: CRC ¼ colorectal cancer; NA ¼ not applicable.
Jeffrey J. Jones et alcollection for each of these cohorts raised the concern that any one
cohort might contain systematic bias incidental to the target path-
ologic features. Therefore, the samples from all 3 of these cohorts
were pooled to mitigate any bias that any one collection might
contribute to the discovery process (detailed further in the Results
section). This collective pool was randomly divided in half, pre-
serving the age and gender matching, to create a 138-sample dis-
covery set (69 CRC and 69 control) to be used for classiﬁer training
and a 136-sample validation set to be used for ﬁnal testing.
Primary Data Acquisition
The patient plasma samples were prepared for MRM LC-MS
measurement as follows. The plasma samples were thawed at 4C
for 30 minutes, followed by a 20-fold dilution of 25 mL of plasma
with 475 mL of multiple afﬁnity removal system (MARS) buffer A
(Agilent Technologies). The diluted plasma was ﬁltered through a
0.22-mm ﬁlter (Agilent Technologies), followed by a 5K molecular
weight cutoff (Agilent Technologies) ﬁltration step for lipid
removal. The retentate was reconstituted to 950 mL with MARS
buffer A and transferred to an autosampler vial for immunoafﬁnity
depletion using a 10-mm  100-mm MARS-14 LC column
(Agilent Technologies). The ﬂow-through peak of the immu-
noafﬁnity column was collected into a 2-mL, 96-well plate
(Eppendorf). The entire collected sample volume was transferred to
a new 5K molecular weight cutoff ﬁlter to exchange the MARS A
buffer with 100 mM ammonium bicarbonate before a total protein
assay (total protein assay, Life Technologies). The sample was
transferred to a 2-mL, 96-well plate and lyophilized in a proteomic
CentriVap system (Labconco). The plate was transferred to a TecanEVO150 liquid handler for denaturation with 50% 2,2,2-
triﬂuoroethanol in 100 mM ammonium bicarbonate, reduction
with 200 mM DL-dithiothreitol (Sigma-Aldrich), alkylation with
200 mM iodoacetamide (Arcos), and enzymatic digestion with
trypsin (Promega) for 16 hours at 37C. The digestion was
quenched with 10 mL of neat formic acid and transferred to a 330-
mL, 96-well plate (Costar; Sigma-Aldrich) for lyophilization.
The LC-MS data for the samples were obtained using 6490 triple
quadrupole mass spectrometers coupled to 1290 ultra high pressure
liquid chromatography (UHPLC) instruments (Agilent Technol-
ogy), with a capillary ﬂow electron ionization source used for
ionization. The LC ﬂow rate was optimized at 450 mL/min and
remained stable around 800 bar. High-purity nitrogen gas was used
for collisionally activated dissociation at energies optimized indi-
vidually for each MRM transition. Agilent 1290 autosamplers were
used to deliver a 10-mL injection volume of 3 mg/mL digested
plasma, reconstituted to contain all stable isotope-labeled standard
peptides at 100 fmol/mL, for chromatographic separation on a
ZORBAX rapid resolution high deﬁnition Eclipse Plus C18 column
(Agilent Technologies) with dimensions of 2.1  150 mm and 1.8-
mm particle size. LC mobile phase A was composed of 0.1% formic
acid in water and mobile phase B was composed of 0.1% of formic
acid in acetonitrile. A 30-minute UHPLC linear segment gradient
was used to separate the analytes with the following segments: 3% B
for the ﬁrst 0.5 minute, 3% to 6% for 0.5 minute, 6% to 10% for 2
minutes, 10% to 30% for 18.75 minutes, 30% to 40% for 5 mi-
nutes, 40% to 80% for 1.25 minutes, and held at 80% for 1.25
minutes, before returning to 3% B for 0.75 minute.
The ﬁnal assay was built to minimize the sparse sampling effects
owing to the high frequency in the concurrent analytes measured,
targeting  12 points across a peak for each analyte. The average
number of points across the peak was 16.2  5.4. Within the 30-
minute chromatography proﬁle, each analyte was allocated a 42-
second window for data acquisition with the MS instrument in
dynamic MRM acquisition mode. Minimizing the data acquisition
window allowed for a maximum single-injection analyte capacity of
approximately 1500. Figure 2 shows a plot of concurrency by LC
time with a maximum concurrency of just 100 transitions. The
minimum and maximum dwell times for the described dynamic
MRM acquisition method were 3.19 and 123.75 ms, respectively.
Robustness tests for chromatographic drift indicated approxi-
mately 100 LC-MS injections could be accomplished without
needing to readjust the targeted retention times or replacing reverse
phase LC-MS columns. Figure 3 shows the trend for the retention
time drift over the duration of the experiment. Column exchanges
were triggered when the lower 97.5 quartile in deviation from the
expected retention time was < 21 seconds, representing a loss of
approximately 18 heavy peptide transitions.
Data Reduction
The raw MS data were extracted using the data conversion
module in ProteomeWizard 2.135 and subject to peak picking and
quantitative assessment through proprietary software developed at
Applied Proteomics, Inc. A real-time analytical pipeline was also
developed to archive and process the data ﬁles immediately after
acquisition. The data ﬁles were processed through a series of op-
erations that included moving the ﬁle to a central server, extractionClinical Colorectal Cancer June 2016 - 189
Figure 2 Plot of Concurrent Assay Transitions Across Mass Spectrometry (MS) Elution Time. Median Chromatography Full Width at
Half Maximum for Heavy Peptides Was 3.4 Seconds, 8.6 Seconds at Baseline. Within the 30-Minute Chromatography Proﬁle,
Each Analyte Was Allocated a 42-Second Window for Data Acquisition With the MS Instrument in Dynamic Multiple Reaction
Monitoring Acquisition Mode Resulting in an Number of Points Across Each Peak of 16.2 ± 5.4
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190 -of raw data, data reduction, calculation of metrics, and uploading of
data to a SQL server. An internal web client, accessing the SQL
server, allowed researchers and technicians to monitor the progress,
assess trends, review traces, and download data for ofﬂine analyses.
In addition, algorithms were used to monitor the trends in analyte
retention times and changes in signal abundance, distributing
automated electronic mail alerts when the trends deviated > 2
standard deviations from the expected distribution.
Classiﬁer Discovery and Validation
The classiﬁer discovery and validation data sets consisted of
relative feature concentrations, calculated as the ratio of the unla-
beled peptide peak area to the associated labeled standard peptide
peak area for each transition. No other normalization of the tran-
sitions’ relative abundance was applied before classiﬁer analysis,
because the labeled peptides provided a sufﬁcient internal control.
The missing values for any transition were imputed as the minimumFigure 3 Box Plots (Whiskers at 95% Conﬁdence Interval [CI]) of D
Expected Times for Each Sample Injection. The Close Monit
the Main Chromatography Column Owing to Signiﬁcant Ris
Were Triggered by the Lower 95% CI at 21 Seconds or a Lo
Chromatography Column Was Exchanged Owing to Risk o
Clinical Colorectal Cancer June 2016value for each particular transition. Before model building, the
transitions were log2-transformed and scaled (0 mean, unit variance)
across the patients within each sample cohort. The total number of
transition values used for the classiﬁer analysis was 532 after ﬁltering
for assay performance.
To reduce the total number of predictor candidates in the clas-
siﬁer models, an initial transition ﬁltering step was performed on the
discovery set using 11 different methods provided by the FSelector
R package36 (correlation selection, c2 ﬁltering, consistency ﬁltering,
linear correlation ﬁltering, rank correlation ﬁltering, information
gain ﬁltering, gain ratio ﬁltering, symmetric uncertainty ﬁltering,
OneR ﬁltering, random forest ﬁltering, and RReliefR ﬁltering). A
total set of 43 transitions was obtained by retaining all transitions
selected by  1 of the feature selection methods. Because this initial
transition-ﬁltering step used only the discovery set data, the holdout
validation set provided a completely independent assessment of the
transitions’ classiﬁcation performance.ifferences of Measured Heavy Peptide Retention Times From
oring of Retention Time Drift Was Used to Justify the Exchange of
k to Losing Peak Measurements (A). Events for Column Exchange
ss of Approximately 17 Heavy Peptide Transitions. Additionally, a
f Liquid Chromatography Over Pressure (B)
Jeffrey J. Jones et alThe classiﬁer models were assessed using a 10-by-10-fold cross-
validation procedure. For each single 10-fold cross-validation, the
138 paired samples in the discovery set were randomly assigned to 1
of 10 folds. Nine of these folds were pooled together as a training
set, and the remaining fold was used as the test set. This method
was repeated 10 times, such that each fold was held out once for
cross-validation testing. Within each fold cycle, transition selection
was ﬁrst applied to the training set using elastic net regularization
implemented in the GLMNet R package.37 In this process, elastic
net models were built, and the model coefﬁcients were used to
select the top n transitions, usually ranging from 2 to 20 transitions.
A classiﬁer model was built with the selected transitions using one
of several different algorithms, including support vector machines,
random forests, elastic network models, logistic regression, and k-
nearest neighbors models. After construction of the classiﬁer model
on the given fold’s training set, the model was directly applied,
without modiﬁcation, to that fold’s test set. Test set performance
was evaluated using its receiver operating characteristic (ROC)
curve and its associated AUC. After these 10 internal cycles, the
total discovery set was once again randomly divided into 10 folds,
and the procedure was repeated for a total of 10 outer cycles. The
transition selection and model assembly process was performed
using only the data from each individual fold’s training set. At the
completion of this process, the top-performing models, as assessed
by the discovery set cross-validation AUC values, were selected for
validation. These models were directly applied to the validation setFigure 4 Calibration Curves for a Randomly Selected Set of Heavy
Covering Individual Peptide Concentrations of 250 fmol/m
Represented in the Point Cluster. A Loess Smooth Line W
Abbreviations: AUC ¼ area under the curve; QQQ ¼ triple quadropole.data, and AUC performance was determined. Despite the evalua-
tion of a large grid of feature selection and classiﬁer assembly pa-
rameters, multiple testing correction concerns were not an issue
because of the hold out of a completely independent validation set
(n ¼ 136).
Statistical Analysis
Data analysis was performed using R.38 ROC analysis and the
graphic data were generated using the ROCR R package.39
Results
Assay Performance
The performance of the MS-MRM assays for the 187 targeted
proteins was assessed after LC-MS data collection by the ability to
detect the presence of endogenous peptides in  50% of the dis-
covery set samples. The criterion for detection was deﬁned by the
observation of a chromatographic peak of approximately Gaussian
shape with a 4- to 8-second full-width at half-maximum. In addi-
tion, the peak center of the endogenous analyte was required to have
been within 2 seconds of the peak center for the internal heavy
peptide standard. By this deﬁnition of assay performance, 424
transitions, 260 peptides, and 168 proteins of the initial list of 187
targets were quantitatively measured, with an assay development
success rate of 90%. For the 674 stable isotope peptides used in the
present study, the median coefﬁcient of variation for both in-
struments was 0.214 and 0.228. Figure 4 shows the 5-point dilutionPeptide Transitions, Showing the 5-Point Daily Calibration Curve
L to 0.025 fmol/mL. All 12 Days, on Each Instrument, Are
as Plotted to Guide the Eye
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Table 2 Proteins, Peptides, and Transitions Constituting 13-Protein/15-Transition Validated Classiﬁer for CRC Detection Using
Targeted MS-MRM
Protein Description Protein ID Peptide Transition
a1-Acid glycoprotein 1 A1AG1_HUMAN NWGLSVYADK y7
a1-Acid glycoprotein 1 A1AG1_HUMAN SDVVYTDWK y5
a1-Antitrypsin A1AT_HUMAN SVLGQLGITK y7
a-Amylase 2B AMY2B_HUMAN LVGLLDLALEKDYVR b3
Clusterin CLUS_HUMAN EPQDTYHYLPFSLPHR y3
Complement component C9 CO9_HUMAN TEHYEEQIEAFK y2
Delta(3,5)-Delta(2,4)-dienoyl-CoA
isomerase, mitochondrial
ECH1_HUMAN LRDLLTR b3
Ferritin light chain FRIL_HUMAN GGRALFQDIK b3
Gelsolin GELS_HUMAN AGALNSNDAFVLK b4
Gelsolin GELS_HUMAN AGALNSNDAFVLK y7
Metalloproteinase inhibitor 1 TIMP1_HUMAN GFQALGDAADIR b4
Osteopontin OSTP_HUMAN AIPVAQDLNAPSDWDSR y9
Selenium-binding protein 1 SBP1_HUMAN EPLGPALAHELR y6
Seprase SEPR_HUMAN LGVYEVEDQITAVR y8
Spondin-2 SPON2_HUMAN HSLVSFVVR y8
Abbreviations: CRC ¼ colorectal cancer; MRM ¼ multiple reaction monitoring; MS ¼ mass spectrometry.
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192 -proﬁle run on each instrument for every day of study collection.
The overall instrument dynamic range was determined to be
approximately 2.5 to 3 orders of magnitude, with good stability and
linearity between both instruments.Figure 5 Average Receiver Operating Characteristic (ROC)
Curve From the 15-Transition and 13-Protein
Classiﬁer Model Applied to the Discovery Set Data in
Cross-Validation Assessment. The Plot Represents
the Average of the 10 ROC Curves Obtained by
Combining Model Predictions for All Test Set
Samples Across the 10 Folds of Each Inner Replicate
of the Cross-Validation Procedure. The Mean Area
Under the Curve of These 10 ROCs Was 0.82
Clinical Colorectal Cancer June 2016Classiﬁer Performance
After assessment of the discovery set classiﬁer models, a classiﬁer
that used the random forest ensemble approach (random forest R
package, version 4.6-7),40 with default parameters and 15 transi-
tions selected by elastic net regularization selected for ﬁnal valida-
tion. A ﬁnal random forest classiﬁer model was built on the entire
discovery set data and locked down before application to the vali-
dation set data. This model was composed of 15 transitions from 13
proteins: A1AG1, A1AT, AMY2B, CLUS, CO9, ECH1, FRIL,
GELS, OSTP, SBP1, SEPR, SPON2, and TIMP1. The names of
the proteins, peptides, and transitions selected for the classiﬁer are
listed in Table 2. The ROC plot for the discovery set cross-
validation is shown in Figure 5, with the error bars representing
the distribution of values from the 10 rounds of the 10-fold cross-
validation. The average AUC from these 10 rounds was 0.82. After
ﬁnal classiﬁer assembly, the performance in the validation set was
0.91 (Figure 6). The gray curves represent the individual classiﬁer
performance for each of the component transitions in the validation
set. At the point of maximum accuracy on the validation ROC
curve (84%), the sensitivity was 87% and the speciﬁcity was 81%.
Overall, 90% of the stage I and II cancers were correctly classiﬁed
(12 of 16 for stage I and 34 of 35 for stage II), suggesting that early
CRC detection with this classiﬁer could be possible.
As described in the Materials and Methods section, to rule out
the potential that a collection bias in 1 of the 3 combined cohorts
used in the present study might inﬂuence classiﬁer assembly and
performance, a permutation analysis was performed. In the present
analysis, the data from each protein in the 15-transition and 13-
protein classiﬁer model were randomly permuted among the sam-
ples and cohorts, 1 protein at a time, leaving the data for the other
proteins intact. For each protein permutation, the classiﬁer model
was applied to the new data set, and the number of samples
correctly and incorrectly classiﬁed by sample cohort was tabulated,
Figure 6 Validation Set Receiver Operating Characteristic
(ROC) Curve for the Locked Discovery Set Model
Applied to the Validation Set (Black Line). The
Associated Area Under the Curve Was 0.91. The ROC
Curves From the Individual Transition Components of
the Classiﬁer Model Are Shown in Light Gray for
Comparative Assessment Against the Combined
Marker Panel Performance
Jeffrey J. Jones et alassessed at the point of maximum accuracy. This resulted in a 2  3
table of the correct and incorrect classiﬁcation versus the 3-sample
cohorts. Fisher’s exact test was then applied to the 2  3 table to
assess the possibility of association of sample misclassiﬁcation with
any of the sample cohorts. None of the resulting P values reached
signiﬁcance (a ¼ 0.05, Bonferroni corrected; Table 3), suggesting
no association was present in the sample cohorts with misclassiﬁ-
cation and that any one particular protein in the classiﬁer was not
selected because of a cohort-speciﬁc bias.Table 3 Results for Tests for Signiﬁcance of Incorrectly Called Sam
Component Permutation Analysis
Protein
Samples With Incorrect Results
Asterand CapitalBio ProteoGenex
A1AG1 4 9 6
A1AT 4 11 7
AMY2B 4 10 9
CLUS 4 12 8
CO9 10 10 10
ECH1 4 13 6
FRIL 4 11 7
GELS 7 9 10
OSTP 4 12 6
SBP1 5 11 7
SEPR 2 10 8
SPON2 3 13 7
TIMP1 5 11 8Discussion
Research efforts in blood-based marker proteins for CRC have, to
date, demonstrated little success in the identiﬁcation of markers
with sufﬁcient performance to be clinically useful. In the present
initial study, using a highly multiplexed approach to measure pro-
teins by targeted MS, we have rapidly evaluated the combined
discovery performance of candidate CRC markers and identiﬁed 
1 group of markers that merit further study in the appropriate pa-
tient subsets.
From a technical perspective, we have demonstrated that targeted
MS is a viable approach to quickly establish assays for the relative
abundance of many a priori interesting proteins that can then be
measured simultaneously in many samples. Of the 187 candidate
CRC marker proteins selected for multiplex targeted MS-MRM,
90% yielded evaluable data after a simple workﬂow according to
abundant protein immunodepletion. No analyte-speciﬁc afﬁnity
reagents (eg, antibodies, aptamers) were used. The total assay
development time was approximately 2 months, and the greatest
expense was for the synthetic, stable-isotope peptide controls. The
rapidity and productivity of this approach suggests that in this and
many other clinical research areas, the ability to combine the per-
formance of previously insufﬁcient marker proteins might produce
useful assays. We have shown the ability to rapidly evaluate and
select from a very large group of initial candidates, using relative
quantiﬁcation by MS, and found  1 group of proteins that merits
further development. Conversion of the identiﬁed marker panel to
more speciﬁc assay formats, either analyte-speciﬁc enrichment mass
spectrometry or traditional multiplex immunoassay, might further
improve precision and accuracy. Such reﬁnement would also in-
crease assay throughput and reduce the costs. Although some studies
have endeavored to identify and combine the markers to improve
performance with more standard approaches (eg, enzyme-linked
immunosorbent assay), the challenges of running many individual
assays on limited amounts of sample material or the technical
limitations of these approaches have kept these studies from
achieving better performance.23-25ples as Function of Individual Cohort as Assessed by Panel
Samples With Correct Result P Value (Fisher’s
Exact Test;
Bonferroni)Asterand CapitalBio ProteoGenex
44 31 42 1.00
44 29 41 0.88
44 30 39 1.00
44 28 40 0.48
38 30 38 1.00
44 27 42 0.14
44 29 41 0.88
41 31 38 1.00
44 28 42 0.29
43 29 41 1.00
46 30 40 0.20
45 27 41 0.06
43 29 40 1.00
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From a clinical research perspective, we have demonstrated the
feasibility of the development of a panel of candidate proteins for
the detection of CRC from a blood plasma sample. Our assay
performance of 87% sensitivity and 81% speciﬁcity at the point of
maximum accuracy (84%) has demonstrated the power of identi-
fying and combining proteins that individually might be not clin-
ically relevant, but, as a group, have signiﬁcant clinical performance.
The results of the present initial study have demonstrated the po-
tential to discover a sufﬁciently performing, noninvasive, blood-
based biomarker panel that could help to improve compliance for
CRC testing in populations ineligible for colonoscopy.Clinical Practice Points
 Patients directed in accordance with current guidelines for CRC
screening (eg, endoscopy, stool-based tests) have not been fully
compliant, in large part because of the inconvenience or sample
format of the currently available tests.
 Despite a long history of attempts, a blood-based, single-protein
test for CRC with sufﬁcient clinical performance has been not be
demonstrated.
 The present study has demonstrated the feasibility of identifying
combinations of candidate protein markers, using high-multiplex
MS, to deﬁne diagnostic tests with superior performance.
 Blood tests for CRC will soon be developed with sufﬁcient
clinical performance and utility to aid in overall CRC detection
and diagnosis.Disclosure
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Supplemental Table 1 List of Selected Proteins
Protein ID Protein Description Peptide Transition
1433Z_HUMAN 14-3-3 Protein zeta/delta VVSSIEQK b3
1433Z_HUMAN 14-3-3 Protein zeta/delta GIVDQSQQAYQEAFEISK y10
1433Z_HUMAN 14-3-3 Protein zeta/delta GIVDQSQQAYQEAFEISK y3
1433Z_HUMAN 14-3-3 Protein zeta/delta VVSSIEQK y3
1A68_HUMAN HLA class I histocompatibility antigen WEAAHVAEQWR b3
1A68_HUMAN HLA class I histocompatibility antigen WVAVVVPSGQEQR b3
1A68_HUMAN HLA class I histocompatibility antigen WEAAHVAEQWR y6
1A68_HUMAN HLA class I histocompatibility antigen WVAVVVPSGQEQR y7
A1AG1_HUMAN a1-Acid glycoprotein 1 SDVVYTDWK b3
A1AG1_HUMAN a1-Acid glycoprotein 1 SDVVYTDWK y5
A1AG1_HUMAN a1-Acid glycoprotein 1 NWGLSVYADK y7
A1AG1_HUMAN a1-Acid glycoprotein 1 NWGLSVYADK y8
A1AT_HUMAN a1-Antitrypsin QINDYVEK y4
A1AT_HUMAN a1-Antitrypsin QINDYVEK y5
A1AT_HUMAN a1-Antitrypsin SVLGQLGITK y6
A1AT_HUMAN a1-Antitrypsin SVLGQLGITK y7
AACT_HUMAN a1-Antichymotrypsin ADLSGITGAR b3
AACT_HUMAN a1-Antichymotrypsin GKITDLIK y3
AACT_HUMAN a1-Antichymotrypsin GKITDLIK y5
AACT_HUMAN a1-Antichymotrypsin HLLPQQSK y5
AACT_HUMAN a1-Antichymotrypsin ADLSGITGAR y6
AACT_HUMAN a1-Antichymotrypsin HLLPQQSK y6
ACTB_HUMAN Actin GYSFTTTAER b3
ACTB_HUMAN Actin GYSFTTTAER y5
ACTH_HUMAN Actin GYSFVTTAER y5
ACTH_HUMAN Actin GYSFVTTAER y6
ACTH_HUMAN Actin PEYDEAGPSIVHR y8
ACTH_HUMAN Actin PEYDEAGPSIVHR y9
ADT2_HUMAN ADP/ATP translocase 2 IYKSDGIK b2
ADT2_HUMAN ADP/ATP translocase 2 LAADVGKAGAER y5
ADT2_HUMAN ADP/ATP translocase 2 IYKSDGIK y6
ADT2_HUMAN ADP/ATP translocase 2 LAADVGKAGAER y8
AKT1_HUMAN RAC-a-serine/threonine protein kinase NDGTFIGYK y4
AKT1_HUMAN RAC-a-serine/threonine protein kinase FPRTLGPEAK y5
AKT1_HUMAN RAC-a-serine/threonine protein kinase NDGTFIGYK y5
AKT1_HUMAN RAC-a-serine/threonine protein kinase FPRTLGPEAK y8
AL1A1_HUMAN Retinal dehydrogenase 1 VAFTGSTEVGK b3
AL1A1_HUMAN Retinal dehydrogenase 1 IFINNEWHDSVSGK y3
AL1A1_HUMAN Retinal dehydrogenase 1 IFINNEWHDSVSGK y7
AL1A1_HUMAN Retinal dehydrogenase 1 VAFTGSTEVGK y7
AL1B1_HUMAN Aldehyde dehydrogenase X AAGDSNLK b2
AL1B1_HUMAN Aldehyde dehydrogenase X LLNLLADLVER y6
AL1B1_HUMAN Aldehyde dehydrogenase X AAGDSNLK y7
AL1B1_HUMAN Aldehyde dehydrogenase X LLNLLADLVER y7
ALBU_HUMAN Serum albumin QTALVELVK y5
ALBU_HUMAN Serum albumin QTALVELVK y7
ALDOA_HUMAN Fructose-bisphosphate aldolase A GILAADESTGSIAK b4
ALDOA_HUMAN Fructose-bisphosphate aldolase A ALQASALK y3
ALDOA_HUMAN Fructose-bisphosphate aldolase A ALQASALK y6
ALDOA_HUMAN Fructose-bisphosphate aldolase A GILAADESTGSIAK y9
ALDR_HUMAN Aldose reductase IAENFK y3
ALDR_HUMAN Aldose reductase IAENFK y4
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Protein ID Protein Description Peptide Transition
ALDR_HUMAN Aldose reductase SPPGQVTEAVK y6
ALDR_HUMAN Aldose reductase SPPGQVTEAVK y8
AMY2B_HUMAN a-Amylase 2B LVGLLDLALEKDYVR b3
AMY2B_HUMAN a-Amylase 2B LVGLLDLALEKDYVR b4
AMY2B_HUMAN a-Amylase 2B LVGLLDLALEK y7
AMY2B_HUMAN a-Amylase 2B LVGLLDLALEK y8
ANGT_HUMAN Angiotensinogen LQAILGVPWK b3
ANGT_HUMAN Angiotensinogen DPTFIPAPIQAK b4
ANGT_HUMAN Angiotensinogen LQAILGVPWK y5
ANGT_HUMAN Angiotensinogen DPTFIPAPIQAK y8
ANXA1_HUMAN Annexin A1 DITSDTSGDFR b3
ANXA1_HUMAN Annexin A1 NALLSLAK y4
ANXA1_HUMAN Annexin A1 NALLSLAK y5
ANXA1_HUMAN Annexin A1 DITSDTSGDFR y6
ANXA3_HUMAN Annexin A3 DYPDFSPSVDAEAIQK b5
ANXA3_HUMAN Annexin A3 DYPDFSPSVDAEAIQK y10
ANXA3_HUMAN Annexin A3 HYGYSLYSAIK y5
ANXA3_HUMAN Annexin A3 HYGYSLYSAIK y7
ANXA4_HUMAN Annexin A4 ISQTYQQQYGR y4
ANXA4_HUMAN Annexin A4 ISQTYQQQYGR y5
ANXA4_HUMAN Annexin A4 GLGTDEDAIISVLAYR y6
ANXA4_HUMAN Annexin A4 GLGTDEDAIISVLAYR y8
ANXA5_HUMAN Annexin A5 VLTEIIASR y3
ANXA5_HUMAN Annexin A5 SEIDLFNIR y5
ANXA5_HUMAN Annexin A5 VLTEIIASR y6
ANXA5_HUMAN Annexin A5 SEIDLFNIR y7
APC_HUMAN Adenomatous polyposis coli protein SERPVLVR b3
APC_HUMAN Adenomatous polyposis coli protein SERPVLVR y5
APOA1_HUMAN Apolipoprotein A-I QGLLPVLESFK y5
APOA1_HUMAN Apolipoprotein A-I QGLLPVLESFK y7
APOA1_HUMAN Apolipoprotein A-I VSFLSALEEYTK y7
APOA1_HUMAN Apolipoprotein A-I VSFLSALEEYTK y8
APOC1_HUMAN Apolipoprotein C-I EFGNTLEDK y3
APOC1_HUMAN Apolipoprotein C-I QSELSAK y3
APOC1_HUMAN Apolipoprotein C-I QSELSAK y4
APOC1_HUMAN Apolipoprotein C-I EFGNTLEDK y6
APOH_HUMAN b2-Glycoprotein 1 EHSSLAFWK b3
APOH_HUMAN b2-Glycoprotein 1 EHSSLAFWK y7
APOH_HUMAN b2-Glycoprotein 1 PDDLPFSTVVPLK y7
APOH_HUMAN b2-Glycoprotein 1 PDDLPFSTVVPLK y9
ATPB_HUMAN ATP synthase subunit-b VVDLLAPYAK b3
ATPB_HUMAN ATP synthase subunit-b IPVGPETLGR y7
ATPB_HUMAN ATP synthase subunit-b VVDLLAPYAK y7
ATPB_HUMAN ATP synthase subunit-b IPVGPETLGR y8
BANK1_HUMAN B-cell scaffold protein with ankyrin repeats LTIVHHPGGK y6
BANK1_HUMAN B-cell scaffold protein with ankyrin repeats LTIVHHPGGK y8
CA195_HUMAN Putative uncharacterized protein C1orf195 SQSLAHPGR y3
CA195_HUMAN Putative uncharacterized protein C1orf195 SQSLAHPGR y6
CA195_HUMAN Putative uncharacterized protein C1orf195 EVLQNTNQYSSK y7
CA195_HUMAN Putative uncharacterized protein C1orf195 EVLQNTNQYSSK y8
CAH1_HUMAN Carbonic anhydrase 1 GGPFSDSYR b3
CAH1_HUMAN Carbonic anhydrase 1 LYPIANGNNQSPVDIK y10
CAH1_HUMAN Carbonic anhydrase 1 GGPFSDSYR y4
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CAH1_HUMAN Carbonic anhydrase 1 LYPIANGNNQSPVDIK y5
CAH2_HUMAN Carbonic anhydrase 2 VVDVLDSIK y3
CAH2_HUMAN Carbonic anhydrase 2 VVDVLDSIK y5
CAH2_HUMAN Carbonic anhydrase 2 EPISVSSEQVLK y8
CAH2_HUMAN Carbonic anhydrase 2 EPISVSSEQVLK y9
CALR_HUMAN Calreticulin QIDNPDYK y3
CALR_HUMAN Calreticulin QIDNPDYK y4
CALR_HUMAN Calreticulin FYALSASFEPFSNK y5
CALR_HUMAN Calreticulin FYALSASFEPFSNK y8
CAPG_HUMAN Macrophage-capping protein EGNPEEDLTADK y8
CAPG_HUMAN Macrophage-capping protein QAALQVAEGFISR y8
CAPG_HUMAN Macrophage-capping protein EGNPEEDLTADK y9
CAPG_HUMAN Macrophage-capping protein QAALQVAEGFISR y9
CATD_HUMAN Cathepsin D QPGITFIAAK y5
CATD_HUMAN Cathepsin D LVDQNIFSFYLSR y7
CATD_HUMAN Cathepsin D QPGITFIAAK y8
CATD_HUMAN Cathepsin D LVDQNIFSFYLSR y9
CATS_HUMAN Cathepsin S GPVSVGVDAR b3
CATS_HUMAN Cathepsin S GPVSVGVDAR y6
CATZ_HUMAN Cathepsin Z NVDGVNYASITR b4
CATZ_HUMAN Cathepsin Z VGDYGSLSGR y6
CATZ_HUMAN Cathepsin Z VGDYGSLSGR y8
CATZ_HUMAN Cathepsin Z NVDGVNYASITR y9
CCR5_HUMAN C-C chemokine receptor type 5 YLAVVHAVFALKAR b3
CCR5_HUMAN C-C chemokine receptor type 5 INVKQIAAR y6
CCR5_HUMAN C-C chemokine receptor type 5 INVKQIAAR y7
CCR5_HUMAN C-C chemokine receptor type 5 YLAVVHAVFALKAR y8
CD20_HUMAN B-lymphocyte antigen CD20 EEVVGLTETSSQPK y10
CD20_HUMAN B-lymphocyte antigen CD20 EQTIEIK y4
CD20_HUMAN B-lymphocyte antigen CD20 EQTIEIK y5
CD20_HUMAN B-lymphocyte antigen CD20 EEVVGLTETSSQPK y8
CD24_HUMAN Signal transducer CD24 MGRAMVAR b4
CD24_HUMAN Signal transducer CD24 MGRAMVAR y5
CD63_HUMAN CD63 antigen IGGWLR b2
CD63_HUMAN CD63 antigen IGGWLR b4
CD63_HUMAN CD63 antigen NNHTASILDR y6
CD63_HUMAN CD63 antigen NNHTASILDR y7
CDD_HUMAN Cytidine deaminase TAIQKAVSEGYK b4
CDD_HUMAN Cytidine deaminase AVSEGYK y4
CDD_HUMAN Cytidine deaminase AVSEGYK y5
CDD_HUMAN Cytidine deaminase TAIQKAVSEGYK y8
CEAM3_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 3 PSISSNNSNPK y5
CEAM3_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 3 TAASIYEELLK y5
CEAM3_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 3 PSISSNNSNPK y6
CEAM3_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 3 TAASIYEELLK y6
CEAM5_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5 INGIPQQHTQVLFIAK b3
CEAM5_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5 INGIPQQHTQVLFIAK b4
CEAM5_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5 QIIGYVIGTQQATPGPAYSGR y4
CEAM5_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5 QIIGYVIGTQQATPGPAYSGR y6
CEAM6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5 LTIESTPFNVAEGK b4
CEAM6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 5 LTIESTPFNVAEGK b5
CEAM6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 EVLLLAHNLPQNR y4
CEAM6_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 6 EVLLLAHNLPQNR y8
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CGHB_HUMAN Choriogonadotropin subunit-b variant 1 APPPSLPSPSR y5
CGHB_HUMAN Choriogonadotropin subunit-b variant 1 APPPSLPSPSR y9
CH3L1_HUMAN Chitinase-3-like protein 1 ILGQQVPYATK y5
CH3L1_HUMAN Chitinase-3-like protein 1 ILGQQVPYATK y6
CH3L1_HUMAN Chitinase-3-like protein 1 VTIDSSYDIAK y6
CH3L1_HUMAN Chitinase-3-like protein 1 VTIDSSYDIAK y9
CH60_HUMAN 60-kDa Heat shock protein TVIIEQSWGSPK b4
CH60_HUMAN 60-kDa Heat shock protein ISSIQSIVPALEIANAHR y11
CH60_HUMAN 60-kDa Heat shock protein ISSIQSIVPALEIANAHR y4
CH60_HUMAN 60-kDa Heat shock protein TVIIEQSWGSPK y9
CLC4D_HUMAN C-type lectin domain family 4 member D LSYFLGLR b4
CLC4D_HUMAN C-type lectin domain family 4 member D LEHHAKLK y3
CLC4D_HUMAN C-type lectin domain family 4 member D LEHHAKLK y5
CLC4D_HUMAN C-type lectin domain family 4 member D LSYFLGLR y7
CLUS_HUMAN Clusterin YVNKEIQNAVNGVK b5
CLUS_HUMAN Clusterin YVNKEIQNAVNGVK y10
CLUS_HUMAN Clusterin EPQDTYHYLPFSLPHR y3
CLUS_HUMAN Clusterin EPQDTYHYLPFSLPHR y4
CNN1_HUMAN Calponin-1 VNVGVK b4
CNN1_HUMAN Calponin-1 VNVGVK y4
CNN1_HUMAN Calponin-1 GPAYGLSAEVK y7
CNN1_HUMAN Calponin-1 GPAYGLSAEVK y8
CO3_HUMAN Complement C3 GYTQQLAFR b4
CO3_HUMAN Complement C3 DFDFVPPVVR y5
CO3_HUMAN Complement C3 DFDFVPPVVR y6
CO3_HUMAN Complement C3 GYTQQLAFR y7
CO9_HUMAN Complement component C9 TEHYEEQIEAFK b3
CO9_HUMAN Complement component C9 DRVVEESELAR b6
CO9_HUMAN Complement component C9 TEHYEEQIEAFK y2
CO9_HUMAN Complement component C9 DRVVEESELAR y6
COR1C_HUMAN Coronin-1C TTDTASVQNEAK b4
COR1C_HUMAN Coronin-1C VGIVAWHPTAR y5
COR1C_HUMAN Coronin-1C VGIVAWHPTAR y6
COR1C_HUMAN Coronin-1C TTDTASVQNEAK y8
CRP_HUMAN C-reactive protein ESDTSYVSLK y3
CRP_HUMAN C-reactive protein ESDTSYVSLK y5
CRP_HUMAN C-reactive protein KAFVFPK y5
CRP_HUMAN C-reactive protein KAFVFPK y6
CRP_HUMAN C-reactive protein GYSIFSYATK y7
CRP_HUMAN C-reactive protein GYSIFSYATK y8
CSF1_HUMAN Macrophage colony-stimulating factor 1 SHSSGSVLPLGELEGR b3
CSF1_HUMAN Macrophage colony-stimulating factor 1 TFYETPLQLLEK b4
CSF1_HUMAN Macrophage colony-stimulating factor 1 SHSSGSVLPLGELEGR y6
CSF1_HUMAN Macrophage colony-stimulating factor 1 TFYETPLQLLEK y7
CTNB1_HUMAN Catenin b1 GLNTIPLFVQLLYSPIENIQR b4
CTNB1_HUMAN Catenin b1 NEGVATYAAAVLFR y10
CTNB1_HUMAN Catenin b1 NEGVATYAAAVLFR y7
CTNB1_HUMAN Catenin b1 GLNTIPLFVQLLYSPIENIQR y9
CUL1_HUMAN Cullin-1 FTAFYASR y3
CUL1_HUMAN Cullin-1 FTAFYASR y4
CUL1_HUMAN Cullin-1 QVTNAVLK y5
CUL1_HUMAN Cullin-1 QVTNAVLK y6
DEF1_HUMAN Neutrophil defensin 1 TLAILAAILLVALQAQAEPLQAR y6
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DEF1_HUMAN Neutrophil defensin 1 TLAILAAILLVALQAQAEPLQAR y8
DESM_HUMAN Desmin DIRAQYETIAAK y2
DESM_HUMAN Desmin DIRAQYETIAAK y3
DESM_HUMAN Desmin QVEVLTNQR y4
DESM_HUMAN Desmin QVEVLTNQR y5
DHSA_HUMAN Succinate dehydrogenase ISKLYGDLK b4
DHSA_HUMAN Succinate dehydrogenase LGANSLLDLVVFGR y5
DHSA_HUMAN Succinate dehydrogenase ISKLYGDLK y7
DHSA_HUMAN Succinate dehydrogenase LGANSLLDLVVFGR y8
DPP4_HUMAN Dipeptidyl peptidase 4 TYTLTDYLK b2
DPP4_HUMAN Dipeptidyl peptidase 4 RQLITEER y4
DPP4_HUMAN Dipeptidyl peptidase 4 RQLITEER y6
DPP4_HUMAN Dipeptidyl peptidase 4 TYTLTDYLK y6
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 LAELRGVPR b7
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 LAELRGVPR y4
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 SRLAELR y4
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 SRLAELR y5
DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 IFVFEPPPGVK y5
DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 IFVFEPPPGVK y6
DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 ILDDDTIITTLENLK y7
DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 ILDDDTIITTLENLK y8
ECH1_HUMAN Delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, mitochondrial LRDLLTR b3
ECH1_HUMAN Delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, mitochondrial VIGNQSLVNELAFTAR b5
ECH1_HUMAN Delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, mitochondrial LRDLLTR y5
ECH1_HUMAN Delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, mitochondrial VIGNQSLVNELAFTAR y8
EF2_HUMAN Elongation factor 2 VFSGLVSTGLK y5
EF2_HUMAN Elongation factor 2 EGIPALDNFLDK y6
EF2_HUMAN Elongation factor 2 EGIPALDNFLDK y7
EF2_HUMAN Elongation factor 2 VFSGLVSTGLK y8
ENOA_HUMAN a-Enolase DATNVGDEGGFAPNILENK b5
ENOA_HUMAN a-Enolase DATNVGDEGGFAPNILENK y10
ENPL_HUMAN Endoplasmin SGYLLPDTK b3
ENPL_HUMAN Endoplasmin FAFQAEVNR y5
ENPL_HUMAN Endoplasmin SGYLLPDTK y5
ENPL_HUMAN Endoplasmin FAFQAEVNR y6
EZRI_HUMAN Ezrin SQEQLAAELAEYTAK b3
EZRI_HUMAN Ezrin SQEQLAAELAEYTAK y10
EZRI_HUMAN Ezrin IQVWHAEHR y6
EZRI_HUMAN Ezrin IQVWHAEHR y7
FAK1_HUMAN Focal adhesion kinase 1 LIQQTFR y4
FAK1_HUMAN Focal adhesion kinase 1 VYENVTGLVK y5
FAK1_HUMAN Focal adhesion kinase 1 LIQQTFR y6
FAK1_HUMAN Focal adhesion kinase 1 VYENVTGLVK y8
FAK2_HUMAN Protein tyrosine kinase 2-b EVGYLEFTGPPQK b4
FAK2_HUMAN Protein tyrosine kinase 2-b EVGYLEFTGPPQK y8
FBX4_HUMAN F-box only protein 4 SLPDLEILK y4
FBX4_HUMAN F-box only protein 4 SLPDLEILK y6
FHL1_HUMAN Four and a half LIM domains protein 1 QVIGTGSFFPK y6
FHL1_HUMAN Four and a half LIM domains protein 1 QVIGTGSFFPK y8
FIBB_HUMAN Fibrinogen-b chain DNDGWLTSDPR y5
FIBB_HUMAN Fibrinogen-b chain DNDGWLTSDPR y6
FIBB_HUMAN Fibrinogen-b chain QGFGNVATNTDGK y6
FIBB_HUMAN Fibrinogen-b chain QGFGNVATNTDGK y8
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FIBG_HUMAN Fibrinogen-g chain YLQEIYNSNNQK b4
FIBG_HUMAN Fibrinogen-g chain RLDGSVDFK y3
FIBG_HUMAN Fibrinogen-g chain RLDGSVDFK y6
FIBG_HUMAN Fibrinogen-g chain YLQEIYNSNNQK y8
FLNA_HUMAN Filamin-A VPVHDVTDASK y7
FLNA_HUMAN Filamin-A VPVHDVTDASK y8
FRIH_HUMAN Ferritin heavy chain YFLHQSHEER y5
FRIH_HUMAN Ferritin heavy chain ELGDHVTNLR y7
FRIH_HUMAN Ferritin heavy chain YFLHQSHEER y7
FRIH_HUMAN Ferritin heavy chain ELGDHVTNLR y8
FRIL_HUMAN Ferritin light chain GGRALFQDIK b3
FRIL_HUMAN Ferritin light chain GGRALFQDIK b5
FRIL_HUMAN Ferritin light chain KPAEDEWGK y3
FRIL_HUMAN Ferritin light chain KPAEDEWGK y8
FRMD3_HUMAN FERM domain-containing protein 3 NTGVPLPK b3
FRMD3_HUMAN FERM domain-containing protein 3 EVVEASSK y4
FRMD3_HUMAN FERM domain-containing protein 3 NTGVPLPK y4
FRMD3_HUMAN FERM domain-containing protein 3 EVVEASSK y6
FUCO_HUMAN Tissue a-L-fucosidase NTTSVWYTSK y5
FUCO_HUMAN Tissue a-L-fucosidase DGLIVPIFQER y6
FUCO_HUMAN Tissue a-L-fucosidase DGLIVPIFQER y7
FUCO_HUMAN Tissue a-L-fucosidase NTTSVWYTSK y7
FUCO2_HUMAN Plasma a-L-fucosidase RQFPVSK b3
FUCO2_HUMAN Plasma a-L-fucosidase RQFPVSK y4
FUCO2_HUMAN Plasma a-L-fucosidase EKLVYAIFLK y5
FUCO2_HUMAN Plasma a-L-fucosidase EKLVYAIFLK y7
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase LVINGNPITIFQER b3
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase GALQNIIPASTGAAK y10
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase GALQNIIPASTGAAK y11
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase LVINGNPITIFQER y9
GBRA1_HUMAN g-Aminobutyric acid receptor subunit a1 VKDPLIK b5
GBRA1_HUMAN g-Aminobutyric acid receptor subunit a1 FGSYAYTR y3
GBRA1_HUMAN g-Aminobutyric acid receptor subunit a1 FGSYAYTR y5
GBRA1_HUMAN g-Aminobutyric acid receptor subunit a1 VKDPLIK y5
GDF15_HUMAN Growth differentiation factor 15 RYEDLLTR b3
GDF15_HUMAN Growth differentiation factor 15 ISRAALPEGLPEASR b6
GDF15_HUMAN Growth differentiation factor 15 RYEDLLTR y4
GDF15_HUMAN Growth differentiation factor 15 ISRAALPEGLPEASR y7
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 AEEYEFLTPVEEAPK b5
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 AEEYEFLTPVEEAPK y10
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 YIQHTYR y5
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 YIQHTYR y6
GELS_HUMAN Gelsolin AGALNSNDAFVLK b4
GELS_HUMAN Gelsolin AGALNSNDAFVLK y7
GRP75_HUMAN Stress-70 protein QAVTNPNNTFYATK b3
GRP75_HUMAN Stress-70 protein RDYASEAIK b6
GRP75_HUMAN Stress-70 protein RDYASEAIK b7
GRP75_HUMAN Stress-70 protein QAVTNPNNTFYATK y7
GSTP1_HUMAN Glutathione S-transferase P FQDGDLTLYQSNTILR b3
GSTP1_HUMAN Glutathione S-transferase P AFLASPEYVNLPINGNGK b4
GSTP1_HUMAN Glutathione S-transferase P AFLASPEYVNLPINGNGK y5
GSTP1_HUMAN Glutathione S-transferase P FQDGDLTLYQSNTILR y8
HABP2_HUMAN Hyaluronan-binding protein 2 RPGVYTQVTK b4
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HABP2_HUMAN Hyaluronan-binding protein 2 RPGVYTQVTK b5
HABP2_HUMAN Hyaluronan-binding protein 2 DEIPHNDIALLK y5
HABP2_HUMAN Hyaluronan-binding protein 2 DEIPHNDIALLK y9
HGF_HUMAN Hepatocyte growth factor AFVFDK b3
HGF_HUMAN Hepatocyte growth factor NTIHEFK b3
HGF_HUMAN Hepatocyte growth factor AFVFDK y3
HGF_HUMAN Hepatocyte growth factor VAYYAK y3
HGF_HUMAN Hepatocyte growth factor NTIHEFK y4
HGF_HUMAN Hepatocyte growth factor VAYYAK y4
HMGB1_HUMAN High-mobility group protein B1 GKPDAAK y4
HMGB1_HUMAN High-mobility group protein B1 GKPDAAK y5
HMGB1_HUMAN High-mobility group protein B1 HPDASVNFSEFSK y7
HMGB1_HUMAN High-mobility group protein B1 HPDASVNFSEFSK y8
HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F YIGIVK b3
HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F ITGEAFVQFASQELAEK b6
HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F YIGIVK y5
HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F ITGEAFVQFASQELAEK y9
HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q SENQEFYQDTFGQQWK b4
HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q SENQEFYQDTFGQQWK y5
HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q NLANTVTEEILEK y7
HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q NLANTVTEEILEK y8
HPT_HUMAN Haptoglobin HYEGSTVPEK b3
HPT_HUMAN Haptoglobin TEGDGVYTLNNEK b3
HPT_HUMAN Haptoglobin TEGDGVYTLNNEK b4
HPT_HUMAN Haptoglobin HYEGSTVPEK y7
HS90B_HUMAN Heat shock protein HSP 90-b HLEINPDHPIVETLR y10
HS90B_HUMAN Heat shock protein HSP 90-b HLEINPDHPIVETLR y8
HSPB1_HUMAN Heat shock protein b1 DGVVEITGK y5
HSPB1_HUMAN Heat shock protein b1 QLSSGVSEIR y5
HSPB1_HUMAN Heat shock protein b1 DGVVEITGK y6
HSPB1_HUMAN Heat shock protein b1 QLSSGVSEIR y6
IF4A3_HUMAN Eukaryotic initiation factor 4A-III ELAVQIQK y4
IF4A3_HUMAN Eukaryotic initiation factor 4A-III EQIYDVYR y5
IF4A3_HUMAN Eukaryotic initiation factor 4A-III ELAVQIQK y6
IF4A3_HUMAN Eukaryotic initiation factor 4A-III EQIYDVYR y6
IFT74_HUMAN Intraﬂagellar transport protein 74 homolog ISELTTEVNK y5
IFT74_HUMAN Intraﬂagellar transport protein 74 homolog ISELTTEVNK y6
IGF1_HUMAN Insulin-like growth factor IA ISSLPTQLFK b4
IGF1_HUMAN Insulin-like growth factor IA NASRGSAGNK y6
IGF1_HUMAN Insulin-like growth factor IA ISSLPTQLFK y7
IGF1_HUMAN Insulin-like growth factor IA NASRGSAGNK y7
IGHA2_HUMAN Ig a2 chain C region TPLTANITK b3
IGHA2_HUMAN Ig a2 chain C region TPLTANITKSGNTFR b4
IGHA2_HUMAN Ig a2 chain C region TPLTANITK y7
IGHA2_HUMAN Ig a2 chain C region TPLTANITKSGNTFR y8
IL2RB_HUMAN Interleukin-2 receptor subunit b EGVSFPWSR b3
IL2RB_HUMAN Interleukin-2 receptor subunit b NTGPWLK b4
IL2RB_HUMAN Interleukin-2 receptor subunit b NTGPWLK y3
IL2RB_HUMAN Interleukin-2 receptor subunit b EGVSFPWSR y5
IL8_HUMAN Interleukin-8 ENWVQR y3
IL8_HUMAN Interleukin-8 ENWVQR y5
IL9_HUMAN Interleukin-9 YPLIFSRVK y4
IL9_HUMAN Interleukin-9 SLLEIFQK y5
Jeffrey J. Jones et al
Clinical Colorectal Cancer June 2016 - 194.e7
Supplemental Table 1 Continued
Protein ID Protein Description Peptide Transition
IL9_HUMAN Interleukin-9 SLLEIFQK y6
IL9_HUMAN Interleukin-9 YPLIFSRVK y7
ILEU_HUMAN Leukocyte elastase inhibitor TYNFLPEFLVSTQK b4
ILEU_HUMAN Leukocyte elastase inhibitor KIEEQLTLEK y7
ILEU_HUMAN Leukocyte elastase inhibitor KIEEQLTLEK y8
ILEU_HUMAN Leukocyte elastase inhibitor TYNFLPEFLVSTQK y9
IPYR_HUMAN Inorganic pyrophosphatase DPLNPIKQDVK b4
IPYR_HUMAN Inorganic pyrophosphatase DPLNPIK y4
IPYR_HUMAN Inorganic pyrophosphatase DPLNPIK y5
IPYR_HUMAN Inorganic pyrophosphatase DPLNPIKQDVK y7
ISK1_HUMAN Pancreatic secretory trypsin inhibitor QTSILIQK y3
ISK1_HUMAN Pancreatic secretory trypsin inhibitor QTSILIQK y5
K1C19_HUMAN Keratin, type I cytoskeletal 19 NHEEEISTLR b3
K1C19_HUMAN Keratin, type I cytoskeletal 19 NHEEEISTLR y7
K1C19_HUMAN Keratin, type I cytoskeletal 19 ALEAANGELEVK y8
K1C19_HUMAN Keratin, type I cytoskeletal 19 ALEAANGELEVK y9
K2C8_HUMAN Keratin, type II cytoskeletal 8 ASLEAAIADAEQR y7
K2C8_HUMAN Keratin, type II cytoskeletal 8 LEGLTDEINFLR y7
K2C8_HUMAN Keratin, type II cytoskeletal 8 ASLEAAIADAEQR y8
K2C8_HUMAN Keratin, type II cytoskeletal 8 LEGLTDEINFLR y8
KCRB_HUMAN Creatine kinase B-type LPNLGKHEK b3
KCRB_HUMAN Creatine kinase B-type VLTPELYAELR b3
KCRB_HUMAN Creatine kinase B-type LPNLGKHEK y6
KCRB_HUMAN Creatine kinase B-type VLTPELYAELR y7
KPCD1_HUMAN Serine/threonine-protein kinase D1 LPEHITK b4
KPCD1_HUMAN Serine/threonine-protein kinase D1 LPEHITK y5
KPCD1_HUMAN Serine/threonine-protein kinase D1 DVAIKIIDK y6
KPCD1_HUMAN Serine/threonine-protein kinase D1 DVAIKIIDK y7
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 TATESFASDPILYR b3
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 TATESFASDPILYR y7
LAMA2_HUMAN Laminin subunit a2 NSHIAIAFDDTK b3
LAMA2_HUMAN Laminin subunit a2 INHADFATVQLR y8
LAMA2_HUMAN Laminin subunit a2 INHADFATVQLR y9
LAMA2_HUMAN Laminin subunit a2 NSHIAIAFDDTK y9
LEG3_HUMAN Galectin-3 IQVLVEPDHFK b3
LEG3_HUMAN Galectin-3 QSVFPFESGK b3
LEG3_HUMAN Galectin-3 QSVFPFESGK y5
LEG3_HUMAN Galectin-3 IQVLVEPDHFK y7
LMNB1_HUMAN Lamin-B1 DAALATALGDK b4
LMNB1_HUMAN Lamin-B1 SLETENSALQLQVTER b4
LMNB1_HUMAN Lamin-B1 SLETENSALQLQVTER y10
LMNB1_HUMAN Lamin-B1 DAALATALGDK y6
MARE1_HUMAN Microtubule-associated protein RP/EB family member 1 LEHEYIQNFK b4
MARE1_HUMAN Microtubule-associated protein RP/EB family member 1 GKFQDNFEFVQWFK y5
MARE1_HUMAN Microtubule-associated protein RP/EB family member 1 GKFQDNFEFVQWFK y7
MARE1_HUMAN Microtubule-associated protein RP/EB family member 1 LEHEYIQNFK y7
MCM4_HUMAN DNA replication licensing factor MCM4 FIDPLAK b3
MCM4_HUMAN DNA replication licensing factor MCM4 LAEAHAKVR b3
MCM4_HUMAN DNA replication licensing factor MCM4 FIDPLAK y4
MCM4_HUMAN DNA replication licensing factor MCM4 LAEAHAKVR y7
MIC1_HUMAN Uncharacterized protein C18orf8 HQVLAALR y5
MIC1_HUMAN Uncharacterized protein C18orf8 FEIELPAAPK y6
MIC1_HUMAN Uncharacterized protein C18orf8 HQVLAALR y6
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MIC1_HUMAN Uncharacterized protein C18orf8 FEIELPAAPK y8
MIF_HUMAN Macrophage migration inhibitory factor LRISPDR b3
MIF_HUMAN Macrophage migration inhibitory factor IGGAQNR y4
MIF_HUMAN Macrophage migration inhibitory factor IGGAQNR y5
MIF_HUMAN Macrophage migration inhibitory factor LRISPDR y5
MMP7_HUMAN Matrilysin EIPLHFR b2
MMP7_HUMAN Matrilysin FYLYDSETK b3
MMP7_HUMAN Matrilysin EIPLHFR y5
MMP7_HUMAN Matrilysin FYLYDSETK y6
MMP9_HUMAN Matrix metalloproteinase-9 QSTLVLFPGDLR b4
MMP9_HUMAN Matrix metalloproteinase-9 QSTLVLFPGDLR y7
MMP9_HUMAN Matrix metalloproteinase-9 SLGPALLLLQK y7
MMP9_HUMAN Matrix metalloproteinase-9 SLGPALLLLQK y8
MYL6_HUMAN Myosin light polypeptide 6 EAFQLFDR b4
MYL6_HUMAN Myosin light polypeptide 6 EAFQLFDR y4
MYL9_HUMAN Myosin regulatory light polypeptide 9 GNFNYVEFTR y4
MYL9_HUMAN Myosin regulatory light polypeptide 9 GNFNYVEFTR y6
NDKA_HUMAN Nucleoside diphosphate kinase A DRPFFAGLVK b7
NDKA_HUMAN Nucleoside diphosphate kinase A DRPFFAGLVK y5
NIBL2_HUMAN Niban-like protein 2 AFLDAVR y4
NIBL2_HUMAN Niban-like protein 2 AFLDAVR y5
NNMT_HUMAN Nicotinamide N-methyltransferase HSAESQILK b6
NNMT_HUMAN Nicotinamide N-methyltransferase EAVEAAVK y4
NNMT_HUMAN Nicotinamide N-methyltransferase HSAESQILK y5
NNMT_HUMAN Nicotinamide N-methyltransferase EAVEAAVK y6
OSTP_HUMAN Osteopontin QNLLAPQTLPSK b3
OSTP_HUMAN Osteopontin QNLLAPQTLPSK b4
OSTP_HUMAN Osteopontin AIPVAQDLNAPSDWDSR y8
OSTP_HUMAN Osteopontin AIPVAQDLNAPSDWDSR y9
P53_HUMAN Cellular tumor antigen p53 VEYLDDR y4
P53_HUMAN Cellular tumor antigen p53 VEYLDDR y6
PCKGM_HUMAN Phosphoenolpyruvate carboxykinase ETPIGLVPK y3
PCKGM_HUMAN Phosphoenolpyruvate carboxykinase TLIGHVPDQR y5
PCKGM_HUMAN Phosphoenolpyruvate carboxykinase ETPIGLVPK y6
PCKGM_HUMAN Phosphoenolpyruvate carboxykinase TLIGHVPDQR y7
PDIA3_HUMAN Protein disulﬁde-isomerase A3 LAPEYEAAATR y5
PDIA3_HUMAN Protein disulﬁde-isomerase A3 LAPEYEAAATR y7
PDIA3_HUMAN Protein disulﬁde-isomerase A3 SEPIPESNDGPVK y7
PDIA3_HUMAN Protein disulﬁde-isomerase A3 SEPIPESNDGPVK y9
PDIA6_HUMAN Protein disulﬁde-isomerase A6 LAAVDATVNQVLASR y7
PDIA6_HUMAN Protein disulﬁde-isomerase A6 LAAVDATVNQVLASR y9
PDXK_HUMAN Pyridoxal kinase TVSTLHHVLQR y5
PDXK_HUMAN Pyridoxal kinase TVSTLHHVLQR y6
PDXK_HUMAN Pyridoxal kinase VLSIQSHVIR y6
PDXK_HUMAN Pyridoxal kinase VLSIQSHVIR y7
PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 LYEQLSGK y5
PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 LYEQLSGK y6
PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 LYTLVLTDPDAPSR y6
PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 LYTLVLTDPDAPSR y8
PIPNA_HUMAN Phosphatidylinositol transfer protein a-isoform QELVNQK y2
PIPNA_HUMAN Phosphatidylinositol transfer protein a-isoform VPTFVR y3
PIPNA_HUMAN Phosphatidylinositol transfer protein a-isoform VPTFVR y5
PIPNA_HUMAN Phosphatidylinositol transfer protein a-isoform QELVNQK y6
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PRDX1_HUMAN Peroxiredoxin-1 ADEGISFR y3
PRDX1_HUMAN Peroxiredoxin-1 ADEGISFR y4
PRDX1_HUMAN Peroxiredoxin-1 LVQAFQFTDK y6
PRDX1_HUMAN Peroxiredoxin-1 LVQAFQFTDK y8
PRL_HUMAN Prolactin IDNYLK b3
PRL_HUMAN Prolactin IDNYLKLLK b3
PRL_HUMAN Prolactin IDNYLK y5
PRL_HUMAN Prolactin IDNYLKLLK y7
PSME3_HUMAN Proteasome activator complex subunit 3 ITSEAEDLVANFFPK y6
PSME3_HUMAN Proteasome activator complex subunit 3 ITSEAEDLVANFFPK y7
PTEN_HUMAN Phosphatidylinositol-345-trisphosphate 3-phosphatase and
dual-speciﬁcity protein phosphatase PTEN
NHLDYR b3
PTEN_HUMAN Phosphatidylinositol-345-trisphosphate 3-phosphatase and
dual-speciﬁcity protein phosphatase PTEN
NHLDYR b4
PTEN_HUMAN Phosphatidylinositol-345-trisphosphate 3-phosphatase and
dual-speciﬁcity protein phosphatase PTEN
EYLVLTLTK y5
PTEN_HUMAN Phosphatidylinositol-345-trisphosphate 3-phosphatase and
dual-speciﬁcity protein phosphatase PTEN
EYLVLTLTK y6
RASK_HUMAN GTPase KRas SFEDIHHYR b3
RASK_HUMAN GTPase KRas SFEDIHHYR y6
RBX1_HUMAN RING-box protein 1 EWEFQK b3
RBX1_HUMAN RING-box protein 1 EWEFQK y4
REG4_HUMAN Regenerating islet-derived protein 4 NLLPAWPGLSR y7
REG4_HUMAN Regenerating islet-derived protein 4 SQPIWIGLHDPQK y7
REG4_HUMAN Regenerating islet-derived protein 4 NLLPAWPGLSR y8
REG4_HUMAN Regenerating islet-derived protein 4 SQPIWIGLHDPQK y8
RHOA_HUMAN Transforming protein RhoA NDEHTR b2
RHOA_HUMAN Transforming protein RhoA NDEHTR y3
RHOA_HUMAN Transforming protein RhoA QEPVKPEEGR y5
RHOA_HUMAN Transforming protein RhoA QEPVKPEEGR y6
RHOB_HUMAN Rho-related GTP-binding protein RhoB DLRSDEHVR b5
RHOB_HUMAN Rho-related GTP-binding protein RhoB DLRSDEHVR y3
RHOB_HUMAN Rho-related GTP-binding protein RhoB EVFETATR y3
RHOB_HUMAN Rho-related GTP-binding protein RhoB EVFETATR y6
RHOC_HUMAN Rho-related GTP-binding protein RhoC QEPVRSEEGR b3
RHOC_HUMAN Rho-related GTP-binding protein RhoC DLRQDEHTR b5
RHOC_HUMAN Rho-related GTP-binding protein RhoC DLRQDEHTR y5
RHOC_HUMAN Rho-related GTP-binding protein RhoC QEPVRSEEGR y5
ROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1 GGGFGGNDNFGR y5
ROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1 GGGFGGNDNFGR y7
ROA1_HUMAN Putative heterogeneous nuclear ribonucleoprotein
A1-like protein 3
SESPKEPEQLR y7
ROA1_HUMAN Putative heterogeneous nuclear ribonucleoprotein
A1-like protein 3
SESPKEPEQLR y8
ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 YHTINGHNAEVR b3
ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 YHTINGHNAEVR y7
RRBP1_HUMAN Ribosome-binding protein 1 EHTSHLEAELEK b3
RRBP1_HUMAN Ribosome-binding protein 1 EHTSHLEAELEK y8
RSSA_HUMAN 40S Ribosomal protein SA LLVVTDPR y4
RSSA_HUMAN 40S Ribosomal protein SA LLVVTDPR y5
RSSA_HUMAN 40S Ribosomal protein SA SDGIYIINLK y6
RSSA_HUMAN 40S Ribosomal protein SA SDGIYIINLK y8
S10A8_HUMAN Protein S100-A8 GADVWFK b3
S10A8_HUMAN Protein S100-A8 GADVWFK y5
Plasma-Based Protein Marker Panel for CRC Detection
194.e10 - Clinical Colorectal Cancer June 2016
Supplemental Table 1 Continued
Protein ID Protein Description Peptide Transition
S10A8_HUMAN Protein S100-A8 ALNSIIDVYHK y6
S10A8_HUMAN Protein S100-A8 ALNSIIDVYHK y7
S10A9_HUMAN Protein S100-A9 LGHPDTLNQGEFK y10
S10A9_HUMAN Protein S100-A9 DLQNFLK y5
S10A9_HUMAN Protein S100-A9 DLQNFLK y6
S10A9_HUMAN Protein S100-A9 LGHPDTLNQGEFK y9
S10AB_HUMAN Protein S100-A11 DPGVLDR y3
S10AB_HUMAN Protein S100-A11 DPGVLDR y5
S10AB_HUMAN Protein S100-A11 ISSPTETER y5
S10AB_HUMAN Protein S100-A11 ISSPTETER y6
S10AC_HUMAN Protein S100-A12 ELANTIK y2
S10AC_HUMAN Protein S100-A12 ELANTIK y5
S10AC_HUMAN Protein S100-A12 GHFDTLSK y5
S10AC_HUMAN Protein S100-A12 GHFDTLSK y6
SAA1_HUMAN Serum amyloid A protein GPGGVWAAEAISDAR y10
SAA1_HUMAN Serum amyloid A protein GPGGVWAAEAISDAR y7
SAA2_HUMAN Serum amyloid A-2 protein GAEDSLADQAANKWGR y8
SAA2_HUMAN Serum amyloid A-2 protein GAEDSLADQAANKWGR y9
SAHH_HUMAN Adenosylhomocysteinase VPAINVNDSVTK b4
SAHH_HUMAN Adenosylhomocysteinase VADIGLAAWGR y6
SAHH_HUMAN Adenosylhomocysteinase VADIGLAAWGR y7
SAHH_HUMAN Adenosylhomocysteinase VPAINVNDSVTK y8
SBP1_HUMAN Selenium-binding protein 1 EPLGPALAHELR y6
SBP1_HUMAN Selenium-binding protein 1 EPLGPALAHELR y8
SDCG3_HUMAN Serologically deﬁned colon cancer antigen 3 QLVSGAETLNLVAEILK y11
SDCG3_HUMAN Serologically deﬁned colon cancer antigen 3 QLVSGAETLNLVAEILK y6
SDCG3_HUMAN Serologically deﬁned colon cancer antigen 3 TLQISYDALK y6
SDCG3_HUMAN Serologically deﬁned colon cancer antigen 3 TLQISYDALK y7
SEGN_HUMAN Secretagogin IFAYYDVSK b3
SEGN_HUMAN Secretagogin IFAYYDVSK y6
SEGN_HUMAN Secretagogin ILALQENFLLQFK y8
SEGN_HUMAN Secretagogin ILALQENFLLQFK y9
SELPL_HUMAN P-selectin glycoprotein ligand 1 ALGPLLARDR b2
SELPL_HUMAN P-selectin glycoprotein ligand 1 AKSPGLTPEPR y4
SELPL_HUMAN P-selectin glycoprotein ligand 1 ALGPLLARDR y5
SELPL_HUMAN P-selectin glycoprotein ligand 1 AKSPGLTPEPR y8
SEPR_HUMAN Seprase LGVYEVEDQITAVR y10
SEPR_HUMAN Seprase LLYAVYR y4
SEPR_HUMAN Seprase LLYAVYR y5
SEPR_HUMAN Seprase LGVYEVEDQITAVR y8
SEPT9_HUMAN Septin-9 SITHDIEEK y6
SEPT9_HUMAN Septin-9 SITHDIEEK y7
SF3B3_HUMAN Splicing factor 3B subunit 3 DLILNPR y3
SF3B3_HUMAN Splicing factor 3B subunit 3 IVPGQFLAVDPK y3
SF3B3_HUMAN Splicing factor 3B subunit 3 DLILNPR y4
SF3B3_HUMAN Splicing factor 3B subunit 3 IVPGQFLAVDPK y8
SIAL_HUMAN Bone sialoprotein 2 AGDITNK y3
SIAL_HUMAN Bone sialoprotein 2 AGDITNK y6
SIAL_HUMAN Bone sialoprotein 2 IEDSEENGVFK y7
SIAL_HUMAN Bone sialoprotein 2 IEDSEENGVFK y8
SKP1_HUMAN S-phase kinase-associated protein 1 RTDDIPVWDQEFLK b3
SKP1_HUMAN S-phase kinase-associated protein 1 RTDDIPVWDQEFLK b4
SPB6_HUMAN Serpin B6 IAELLSPGSVDPLTR b4
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SPB6_HUMAN Serpin B6 IAELLSPGSVDPLTR b5
SPB6_HUMAN Serpin B6 LVLVNAVYFR y6
SPB6_HUMAN Serpin B6 LVLVNAVYFR y7
SPON2_HUMAN Spondin-2 NQYVSNGLR b3
SPON2_HUMAN Spondin-2 HSLVSFVVR y7
SPON2_HUMAN Spondin-2 NQYVSNGLR y7
SPON2_HUMAN Spondin-2 HSLVSFVVR y8
SRC_HUMAN Proto-oncogene tyrosine-protein kinase Src LDSGGFYITSR y5
SRC_HUMAN Proto-oncogene tyrosine-protein kinase Src LDSGGFYITSR y7
STK11_HUMAN Serine/threonine-protein kinase 11 LFENIGK y3
STK11_HUMAN Serine/threonine-protein kinase 11 LFENIGK y5
SYDC_HUMAN Aspartyl-tRNA synthetase VFSIGPVFR y4
SYDC_HUMAN Aspartyl-tRNA synthetase FLEPTLR y5
SYDC_HUMAN Aspartyl-tRNA synthetase FLEPTLR y6
SYDC_HUMAN Aspartyl-tRNA synthetase VFSIGPVFR y7
SYG_HUMAN Glycyl-tRNA synthetase VPLVAEK y3
SYG_HUMAN Glycyl-tRNA synthetase VPLVAEK y4
SYG_HUMAN Glycyl-tRNA synthetase TFFSFPAVVAPFK y8
SYG_HUMAN Glycyl-tRNA synthetase TFFSFPAVVAPFK y9
TAL1_HUMAN T-cell acute lymphocytic leukemia protein 1 LSKNEILR y5
TAL1_HUMAN T-cell acute lymphocytic leukemia protein 1 LSKNEILR y7
TBB1_HUMAN Tubulin b1 chain EVDQQLLSVQTR y5
TBB1_HUMAN Tubulin b1 chain ISVYYNEAYGR y6
TBB1_HUMAN Tubulin b1 chain ISVYYNEAYGR y7
TBB1_HUMAN Tubulin b1 chain EVDQQLLSVQTR y8
TCTP_HUMAN Translationally controlled tumor protein HILANFK y4
TCTP_HUMAN Translationally controlled tumor protein HILANFK y5
THTR_HUMAN Thiosulfate sulfurtransferase RFQLVDSR b3
THTR_HUMAN Thiosulfate sulfurtransferase VLDASWYSPGTR b3
THTR_HUMAN Thiosulfate sulfurtransferase RFQLVDSR b4
THTR_HUMAN Thiosulfate sulfurtransferase VLDASWYSPGTR y6
TIMP1_HUMAN Metalloproteinase inhibitor 1 AKFVGTPEVNQTTLYQR b4
TIMP1_HUMAN Metalloproteinase inhibitor 1 GFQALGDAADIR b4
TIMP1_HUMAN Metalloproteinase inhibitor 1 AKFVGTPEVNQTTLYQR b6
TIMP1_HUMAN Metalloproteinase inhibitor 1 GFQALGDAADIR y2
TKT_HUMAN Transketolase AVELAANTK y4
TKT_HUMAN Transketolase AVELAANTK y5
TKT_HUMAN Transketolase DAIAQAVR y5
TKT_HUMAN Transketolase DAIAQAVR y6
TMG4_HUMAN Transmembrane g-carboxyglutamic acid protein 4 EEANFFIHR b4
TMG4_HUMAN Transmembrane g-carboxyglutamic acid protein 4 EIFVDEDK y4
TMG4_HUMAN Transmembrane g-carboxyglutamic acid protein 4 EIFVDEDK y6
TMG4_HUMAN Transmembrane g-carboxyglutamic acid protein 4 EEANFFIHR y7
TNF6B_HUMAN Tumor necrosis factor receptor superfamily member 6B RLTELLGAQDGALLVR b10
TNF6B_HUMAN Tumor necrosis factor receptor superfamily member 6B AVIDFVAFQDISIK b3
TNF6B_HUMAN Tumor necrosis factor receptor superfamily member 6B RLTELLGAQDGALLVR y10
TNF6B_HUMAN Tumor necrosis factor receptor superfamily member 6B AVIDFVAFQDISIK y9
TPM2_HUMAN Tropomyosin b-chain TIDDLEETLASAK b3
TPM2_HUMAN Tropomyosin b-chain TIDDLEETLASAK b4
TPM2_HUMAN Tropomyosin b-chain SLEAQADK y4
TPM2_HUMAN Tropomyosin b-chain SLEAQADK y6
TR10B_HUMAN Tumor necrosis factor receptor superfamily member 10B GQNAPAASGAR b4
TR10B_HUMAN Tumor necrosis factor receptor superfamily member 10B GQNAPAASGAR y7
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TR10B_HUMAN Tumor necrosis factor receptor superfamily member 10B VAKAEAAGHR y7
TR10B_HUMAN Tumor necrosis factor receptor superfamily member 10B VAKAEAAGHR y8
TRAP1_HUMAN Heat shock protein 75 kDa DVLQQRLIK b3
TRAP1_HUMAN Heat shock protein 75 kDa DVLQQRLIK y4
TRAP1_HUMAN Heat shock protein 75 kDa ELISNASDALEKLR y7
TRAP1_HUMAN Heat shock protein 75 kDa ELISNASDALEKLR y8
TRFE_HUMAN Serotransferrin HSTIFENLANK y3
TRFE_HUMAN Serotransferrin DGAGDVAFVK y7
TRFE_HUMAN Serotransferrin HSTIFENLANK y7
TRFE_HUMAN Serotransferrin DGAGDVAFVK y8
TSG6_HUMAN Tumor necrosis factor-inducible gene 6 protein FLSDASVTAGGFQIK y10
TSG6_HUMAN Tumor necrosis factor-inducible gene 6 protein TGIIDYGIR y5
TSG6_HUMAN Tumor necrosis factor-inducible gene 6 protein FLSDASVTAGGFQIK y6
TSG6_HUMAN Tumor necrosis factor-inducible gene 6 protein TGIIDYGIR y6
TSP1_HUMAN Thrombospondin-1 GTLLALER y5
TSP1_HUMAN Thrombospondin-1 IPESGGDNSVFDIFELTGAAR y5
TSP1_HUMAN Thrombospondin-1 GTLLALER y6
TSP1_HUMAN Thrombospondin-1 IPESGGDNSVFDIFELTGAAR y8
UGDH_HUMAN UDP-glucose 6-dehydrogenase DLKNPDR y4
UGDH_HUMAN UDP-glucose 6-dehydrogenase ESSSIYISK y4
UGDH_HUMAN UDP-glucose 6-dehydrogenase DLKNPDR y5
UGDH_HUMAN UDP-glucose 6-dehydrogenase ESSSIYISK y5
UGPA_HUMAN UTP-glucose-1-phosphate uridylyltransferase SFENSLGINVPR b3
UGPA_HUMAN UTP-glucose-1-phosphate uridylyltransferase SFENSLGINVPR y8
UROK_HUMAN Urokinase-type plasminogen activator VSHFLPWIR y4
UROK_HUMAN Urokinase-type plasminogen activator VSHFLPWIR y5
VEGFA_HUMAN Vascular endothelial growth factor A SWSVYVGAR b2
VEGFA_HUMAN Vascular endothelial growth factor A QLELNER y3
VEGFA_HUMAN Vascular endothelial growth factor A SWSVYVGAR y3
VEGFA_HUMAN Vascular endothelial growth factor A QLELNER y4
VEGFA_HUMAN Vascular endothelial growth factor A TVDAAASR y4
VEGFA_HUMAN Vascular endothelial growth factor A TVDAAASR y6
VILI_HUMAN Villin-1 LFQVQGTGANNTK b3
VILI_HUMAN Villin-1 ELKAAVPDTVVEPALK b4
VILI_HUMAN Villin-1 ELKAAVPDTVVEPALK b5
VILI_HUMAN Villin-1 LFQVQGTGANNTK y6
VIME_HUMAN Vimentin FADLSEAANR b3
VIME_HUMAN Vimentin FADLSEAANR y6
VIME_HUMAN Vimentin QDVDNASLAR y6
VIME_HUMAN Vimentin QDVDNASLAR y7
VNN1_HUMAN Pantetheinase FGQTPVQER b3
VNN1_HUMAN Pantetheinase VNFLASNIHYPSK b3
VNN1_HUMAN Pantetheinase VNFLASNIHYPSK y3
VNN1_HUMAN Pantetheinase FGQTPVQER y5
Abbreviations: ADP ¼ adenosine diphosphate; ATP ¼ adenosine triphosphate; CoA ¼ conenzyme A; CRC ¼ colorectal cancer; GTPase ¼ guanosine triphosphatase; HLA ¼ human leukocyte
antigen; UDP ¼ uridine diphosphate; UTP ¼ uridine triphosphate.
Jeffrey J. Jones et al
Clinical Colorectal Cancer June 2016 - 194.e13
